REVIEW ARTICLE |
|
Year : 2017 | Volume
: 65
| Issue : 11 | Page : 1087-1092 |
|
Mitochondrial genetics and therapeutic overview of Leber's hereditary optic neuropathy
Agaath Hedina Manickam1, Minu Jenifer Michael1, Sivasamy Ramasamy2
1 Molecular Genetics and Cancer Biology Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tami Nadu, India 2 Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, Tami Nadu, India
Correspondence Address:
Sivasamy Ramasamy Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore - 641 046, Tami Nadu India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/ijo.IJO_358_17
|
|
Leber's hereditary optic neuropathy (LHON) is a common inherited mitochondrial disorder that is characterized by the degeneration of the optic nerves, leading to vision loss. The major mutations in the mitochondrial genes ND1, ND4, and ND6 of LHON subjects are found to increase the oxidative stress experienced by the optic nerve cell, thereby leading to nerve cell damage. Accurate treatments are not available and drugs that are commercially available like Idebenone, EPI-743, and Bendavia with their antioxidant role help in reducing the oxidative stress experienced by the cell thereby preventing the progression of the disease. Genetic counseling plays an effective role in making the family members aware of the inheritance pattern of the disease. Gene therapy is an alternative for curing the disease but is still under study. This review focuses on the role of mitochondrial genes in causing LHON and therapeutics available for treating the disease. A systematic search has been adopted in various databases using the keywords “LHON,” “mitochondria,” “ND1,” “ND4,” “ND6,” and “therapy” and the following review on mitochondrial genetics and therapeutics of LHON has been developed with obtained articles from 1988 to 2017. |
|
|
|
[FULL TEXT] [PDF]* |
|
|
|